| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 09/26/2002 | WO2001074338A1 Transdermal therapeutic system for the delivery of lerisetron |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137907 Novel compounds |
| 09/26/2002 | US20020137792 Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137775 Novel delta dicarbonyl compounds and methods for using the same |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137723 Low molecular weight polymannuronate |
| 09/26/2002 | US20020137689 Hypolipidemic agents |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441536A1 Polybutene containing chewing gum and confection |
| 09/26/2002 | CA2441202A1 Chemical compounds |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2441042A1 Monoclonal antibody therapy for pancreas cancer |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440480A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2439539A1 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage) |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435664A1 Ncc2705-the genome of a bifidobacterium |
| 09/26/2002 | CA2425902A1 Urocortin-iii and uses thereof |
| 09/26/2002 | CA2404422A1 Preparations for preventing bile acid diarrhea |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 09/25/2002 | EP1243273A1 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
| 09/25/2002 | EP1243256A1 Vaccines absorbable by the transmucosal way |
| 09/25/2002 | EP1242451A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 09/25/2002 | EP1242449A1 Modified adenovirus fibre and uses |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242436A2 Oligosaccharide mixture |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242404A1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242402A2 Novel compounds |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242389A2 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242381A2 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242091A2 Pharmaceutical compositions comprising oxcarbazepine |
| 09/25/2002 | EP1242083A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242067A2 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 09/25/2002 | EP1242064A1 Liver selective therapy |
| 09/25/2002 | EP0925299B1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 09/25/2002 | EP0923550B1 Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists |
| 09/25/2002 | EP0912184B1 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
| 09/25/2002 | EP0817782B1 Phenyl derivatives useful as endothelin receptor antagonists |
| 09/25/2002 | EP0746325B1 Liquid paraffin oil and lactulose-based hypocaloric laxative jelly and method for its preparation |
| 09/25/2002 | EP0702551B1 Compositions and methods for reparation and prevention of fibrotic lesions |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371388A Hexapeptide with stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation differentiation and apoptosis |
| 09/25/2002 | CN1371385A Immunopotentiating compositions |
| 09/25/2002 | CN1371376A Substituted purin derivatives as inhibitors of cell adhesion |
| 09/25/2002 | CN1371374A Substituted heterocycle fused gamma-carbolines |
| 09/25/2002 | CN1371359A Aminobenzophenones as inhibitors IL-1 beta and TNF-alpha |
| 09/25/2002 | CN1371286A Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia |
| 09/25/2002 | CN1371283A Use of propionic bacteria for producing propionic acid and/or propionates in colon |
| 09/25/2002 | CN1371280A Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 09/25/2002 | CN1371277A Pharmaceutical tramadol salts |
| 09/25/2002 | CN1370597A Subhealth treating Chinese medicine prepn and its prepn process |
| 09/25/2002 | CN1370575A Composite prepn for preventing and treating young animal's darrhea and its prepn process |
| 09/25/2002 | CN1370567A Antifatigue Chinese medicine health article |
| 09/25/2002 | CN1370565A Bolus for treating liver and spleen diseases and its production process |
| 09/25/2002 | CN1370562A Hepatitis B treating medicine |
| 09/25/2002 | CN1370557A Ulcer treating capsule and its prepn |